MLLT1
Gene Information
- Official Symbol: MLLT1
- Official Name: MLLT1 super elongation complex subunit
- Aliases and Previous Symbols: N/A
- Entrez ID: 4298
- UniProt: Q03111
- Interactions: BioGRID
- PubMed articles: Open PubMed
- OMIM: Open OMIM
Function Summary
- Entrez Summary: N/A
- UniProt Summary: Component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. {ECO:0000269|PubMed:20159561, ECO:0000269|PubMed:20471948}.
Pfam Domains GO Terms
Pfam Domains
| YEATS |
GO Terms
| transcription elongation factor complex |
| transcription elongation from RNA polymerase II promoter |
| DNA-templated transcription, elongation |
| fibrillar center |
| negative regulation of protein kinase activity |
| negative regulation of kinase activity |
| negative regulation of transferase activity |
| negative regulation of protein phosphorylation |
| negative regulation of phosphorylation |
| transcription by RNA polymerase II |
| negative regulation of phosphate metabolic process |
| negative regulation of phosphorus metabolic process |
| negative regulation of protein modification process |
| transcription, DNA-templated |
| nucleic acid-templated transcription |
| RNA biosynthetic process |
| negative regulation of catalytic activity |
| regulation of protein kinase activity |
| regulation of kinase activity |
| regulation of transferase activity |
| negative regulation of cellular protein metabolic process |
| nucleobase-containing compound biosynthetic process |
| negative regulation of protein metabolic process |
| negative regulation of molecular function |
| heterocycle biosynthetic process |
| aromatic compound biosynthetic process |
| organic cyclic compound biosynthetic process |
| regulation of protein phosphorylation |
| DNA binding |
| DNA-binding transcription factor activity, RNA polymerase II-specific |
| regulation of phosphorylation |
| cellular nitrogen compound biosynthetic process |
| RNA metabolic process |
| cellular macromolecule biosynthetic process |
| macromolecule biosynthetic process |
| regulation of phosphate metabolic process |
| regulation of phosphorus metabolic process |
| regulation of protein modification process |
| gene expression |
CRISPR Data
Compound Hit Most Correlated Genes in Chemogenomics Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Compound Hit
| Screen | Score |
|---|---|
| A-769662 20μM R07 exp331 | -1.75 |
| Vinblastine 0.2μM R03 exp108 | 1.72 |
| Doxorubicin 0.02μM R08 exp478 | 2.16 |
| Nocodazole 0.1μM R03 exp94 | 2.2 |
| THZ1 0.06μM R08 exp531 | 2.4 |
| UM131593 0.2μM R03 exp106 | 3.26 |
Most Correlated Genes in Chemogenomics
| Gene | Correlation |
|---|---|
| MED23 | 0.654 |
| CCDC101 | 0.652 |
| THOC6 | 0.606 |
| RPTOR | 0.596 |
| WDR24 | 0.589 |
| MED16 | 0.583 |
| GNB1L | 0.578 |
| TRIM28 | 0.573 |
| TAF5L | 0.561 |
| ZNF592 | 0.559 |
| DHX29 | 0.558 |
| TLE4 | 0.554 |
| UBE2G1 | 0.552 |
| MED13 | 0.549 |
| OTUD5 | 0.545 |
| TTI2 | 0.539 |
| MEAF6 | 0.532 |
| TAF6L | 0.531 |
| VMP1 | 0.529 |
| BRPF1 | 0.528 |
| TTI1 | 0.524 |
| TADA1 | 0.524 |
| MED13L | 0.52 |
| RNMT | 0.517 |
| ZNF608 | 0.516 |
| DOHH | 0.516 |
| DPAGT1 | 0.515 |
| RTCB | 0.513 |
| ATF7IP | 0.512 |
| HHEX | 0.51 |
| GMPPB | 0.507 |
| MAX | 0.506 |
| TMEM41B | 0.504 |
| FBXO11 | 0.503 |
| PELO | 0.499 |
| AARS | 0.498 |
| SUPT7L | 0.497 |
| GFPT1 | 0.494 |
| UBE3A | 0.491 |
| MED25 | 0.49 |
| MTOR | 0.49 |
| MAPK14 | 0.489 |
| PMM2 | 0.487 |
| CSNK2B | 0.487 |
| PAX5 | 0.482 |
| CBX3 | 0.479 |
| HARS | 0.478 |
| VHL | 0.477 |
| DNAJC3 | 0.475 |
| LAMTOR4 | 0.474 |
| WDR59 | 0.473 |
| CBFB | 0.47 |
| POLR3H | 0.469 |
| UHRF1 | 0.468 |
| BAP1 | 0.468 |
| UBR5 | 0.465 |
| ALG13 | 0.464 |
| FLI1 | 0.46 |
| XPO6 | 0.457 |
| MED4 | 0.456 |
| TADA2B | 0.456 |
| TRMT5 | 0.454 |
| EIF4E | 0.454 |
| ALG1 | 0.451 |
| UBE2G2 | 0.449 |
| VCPIP1 | 0.445 |
| UAP1 | 0.444 |
| USP22 | 0.444 |
| TADA3 | 0.444 |
| UBE2L3 | 0.439 |
| LAMTOR5 | 0.438 |
| TCEB3 | 0.437 |
| GTF3C4 | 0.436 |
| ALG5 | 0.436 |
| TELO2 | 0.436 |
| LSMD1 | 0.434 |
| ATP5J | 0.434 |
| HSPD1 | 0.431 |
| NSD1 | 0.431 |
| THG1L | 0.43 |
| SETDB1 | 0.429 |
| ID3 | 0.429 |
| GTF3C2 | 0.429 |
| DCAF7 | 0.428 |
| PRKAR1A | 0.428 |
| ADSL | 0.427 |
| PAM16 | 0.425 |
| TRIAP1 | 0.424 |
| TP53 | 0.423 |
| SUPT20H | 0.422 |
| NAE1 | 0.422 |
| SLC35B1 | 0.422 |
| MED10 | 0.419 |
| GTF3C6 | 0.418 |
| ARIH1 | 0.416 |
| RPS6KB1 | 0.416 |
| OIP5 | 0.414 |
| LSM11 | 0.411 |
| GTF3C3 | 0.411 |
| TSEN54 | 0.41 |
| ALG2 | 0.409 |
| TRNT1 | 0.408 |
| MIOS | 0.408 |
| YARS | 0.408 |
| MAML1 | 0.407 |
| EXOC4 | 0.407 |
| DR1 | 0.406 |
| POLR3B | 0.405 |
| CARS | 0.404 |
| GPN2 | 0.404 |
| UBE2J1 | 0.404 |
| ELF2 | 0.403 |
| RPN1 | 0.402 |
| SMARCD1 | 0.402 |
| ARL14EP | 0.402 |
| SCAF8 | 0.402 |
| ZFX | 0.401 |
| EPRS | 0.401 |
| SPTY2D1 | 0.4 |
Tissues where Essential in the Avana Dataset (DepMap 20Q1)
Global Fraction of Cell Lines Where Essential: 0/726
| Tissue | Fraction Of Cell Lines Where Essential |
|---|---|
| 1290807.0 | 0/1 |
| 909776.0 | 0/1 |
| bile duct | 0/28 |
| blood | 0/28 |
| bone | 0/25 |
| breast | 0/33 |
| central nervous system | 0/56 |
| cervix | 0/4 |
| colorectal | 0/17 |
| esophagus | 0/13 |
| fibroblast | 0/1 |
| gastric | 0/15 |
| kidney | 0/21 |
| liver | 0/20 |
| lung | 0/75 |
| lymphocyte | 0/14 |
| ovary | 0/26 |
| pancreas | 0/24 |
| peripheral nervous system | 0/16 |
| plasma cell | 0/15 |
| prostate | 0/1 |
| skin | 0/24 |
| soft tissue | 0/7 |
| thyroid | 0/2 |
| upper aerodigestive | 0/22 |
| urinary tract | 0/29 |
| uterus | 0/5 |
Essentiality in NALM6
- Essentiality Rank: 1941
- Expression level (log2 read counts): 6.58
Expression Distribution
MLLT1 Expression in NALM6 Cells: 6.58